Our Funds / Equity Funds

IDFC Tax Advantage (ELSS) Fund

An open ended equity linked saving scheme with a statutory lock in of 3 years and tax benefit

EquityInception Date:26/12/2008
Ask an Advisor

An Equity Linked Savings Scheme (ELSS), with a 3 year lock in, that enables investors to avail of a deduction from total income, as permitted under the Income Tax Act, 1961.

  • Min Investment 500
  • Min SIP Amount 500
  • Exit Load

    Nil

Select
Annualised Returns(as on 30th Apr, 2022)25.68%1yr19.98%3yr15.29%5yr
NAV 90.9600 as on 20/05/20221 Day Change: 2.33(2.59%)

Scheme is suitable for a minimum investment horizon of more than 3 years

Tier 1 Benchmark : S&P BSE 500 TRIAlternate Benchmark : Nifty 50 TRI

Performance as on 29th April 2022

Scheme NamesCAGR Returns (%)Current value of Investment of 10,000
1 year3 year5 year10 year26/12/2008 Since inception1 year3 year5 year10 year26/12/2008 Since inception
IDFC Tax Advantage (ELSS) Fund - Regular Plan - Growth25.6819.9815.2918.1718.6412,56817,30420,38953,21097,870
20.4717.0714.2215.1117.0512,04716,07419,45740,89081,749
16.1414.5914.3414.0215.7111,61415,07119,55637,17870,092
^ Tier 1 Benchmark   |   ^^ Alternate Benchmark   |   ^^^ Tier 2 Benchmark

This fund is managed by Daylynn Pinto (w.e.f 20/10/2016)

View fund performance of other funds managed by Daylynn Pinto

Past performance may or may not be sustained in future.
Regular and Direct Plans have different expense structure. Direct Plan shall have a lower expense ratio excluding distribution expenses, commission expenses etc.

Taxation:

For taxation, please refer the link :  https://bit.ly/3a5CcbE

IDFC Tax Advantage (ELSS) Fund

(Scheme Risk-o-meter)

Investors understand that their principal will be at Very High Risk.

S&P BSE 500 TRI

(Tier 1 Benchmark Risk-o-meter)

This product is suitable for investors who are seeking* :

  • To create wealth over long term.
  • Investment predominantly in Equity and Equity related securities with income tax benefit u/s 80C and 3 years lock-in.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.